INmune Bio Announces $13.0 Million Registered Direct Offering Page 1

Boca Raton, Fla., Sept. 13, 2024 (GLOBE NEWSWIRE) — INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it has entered into securities purchase agreements with new and existing institutional investors and certain directors, officers and employees of the Company (the directors, officers and employees are hereinafter referred to as “Insiders”) for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of its common stock at a combined purchase price per share and related warrant of $5.50 for the institutional investors and $6.50 per share and related warrant for the insiders, pursuant to a registered direct offering. The warrants are exercisable six months after the date of issuance at a price of $6.40 per share and expire five years after the original exercise date. The term of the warrant may be shortened upon the satisfaction of certain conditions. In the case of insiders who participated in the offering, if the expiration date of the warrant falls on a lock-up date, the insiders will have an additional 60 days from the end of the lock-up date to exercise the warrant.

The gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses, will be approximately $13.0 million. The closing of the offering is expected to occur on or about September 16, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

AGP/Alliance Global Partners is acting as sole placement agent for the offering.

This offering is being made pursuant to an effective registration statement on Form S-3 (File No. 333-279036) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on August 7, 2024. A prospectus supplement containing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at . Electronic copies of the prospectus supplement may be obtained when available from AGP/Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060 or by email at. [email protected].